查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951206

蛋白質結晶市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、技術、最終用戶、地區及競爭格局分類，2021-2031年）

Protein Crystallization Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments, Consumables, Software & Services), By Technology, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球蛋白質結晶市場預計將從 2025 年的 22.1 億美元成長到 2031 年的 36.9 億美元，複合年成長率為 8.92%。

這項技術主要透過X光晶體衍射，將蛋白質分子排列成有序的重複晶格，以實現結構解析。該領域的發展主要得益於藥物研發中基於結構的藥物設計方法的日益普及，以及對複雜生物標的高解析度模型的迫切需求。這導致了高通量篩檢所需的特定試劑和自動化液體處理系統的持續需求。 RCSB蛋白質資料庫的數據凸顯了這項技術的廣泛應用，報告顯示，到2024年，將有9,200個生物大分子結構透過X光衍射法解析出來。

市場概覽
預測期 2027-2031
市場規模：2025年 22.1億美元
市場規模：2031年 36.9億美元
複合年成長率：2026-2031年 8.92%
成長最快的細分市場 消耗品
最大的市場 北美洲

儘管呈現正面趨勢，但由於膜蛋白和不穩定大分子複合物結晶的高失敗率，市場仍面臨許多挑戰。晶體形成過程中固有的不確定性常常導致計劃週期延長和研究成本增加。這些經濟和技術障礙阻礙了小規模、資源匱乏的實驗室廣泛採用結晶工作流程，從而限制了該領域的市場擴張。

市場促進因素

製藥和生物技術領域研發投入的不斷成長是蛋白質結晶市場的主要驅動力，推動了先進設備和高純度試劑的購買。隨著藥物研發人員專注於發現新的治療標靶，結構生物學部門的經費投入也不斷增加，以支持解析大分子結構的複雜過程。這一趨勢在主要行業領導者的預算中顯而易見；例如，默克公司在2024年2月報告稱，其2023會計年度的年度研發支出將達到305億美元。如此巨額的投資確保了結晶設施的持續運行，從而能夠分析日益增多的生物候選藥物。此外，美國食品藥物管理局（FDA）藥物評估與研究中心在2024年核准了55種新型治療藥物，也印證了這個成長趨勢。

同時，自動化和高通量篩檢技術的突破正在透過最大限度地減少人為誤差和最佳化實驗密度來提升結晶效率。將人工智慧融入液體處理系統能夠精確預測結晶條件，這是基於結構的藥物設計的關鍵要素。這些創新對於檢驗計算模型至關重要，因為物理晶體仍然是確認原子間相互作用的最終標準。為了凸顯這種協同效應，Google在2024年5月宣布，其AlphaFold 3模型預測蛋白質-配體交互作用的準確率比傳統方法高出50%。這使得檢驗這些預測結果需要建立穩健的實體工作流程。因此，自動化硬體和計算工具的結合正在降低複雜靶點的分析門檻，並擴大市場覆蓋範圍。

市場挑戰

膜蛋白和不穩定大分子複合物結晶的高失敗率導致結構測定效率顯著降低，並嚴重阻礙了全球蛋白質結晶市場的發展。由於這些生物標靶本身難以穩定，研究人員常常經歷反覆的實驗失敗，導致計劃週期延長，並過度消耗昂貴的試劑。這種不可預測性降低了結​​晶工作流程的效率，並直接阻礙了整個產業為提高藥物設計速度和自動化程度所做的努力。

此外，這些失敗帶來的經濟負擔限制了小規模研究機構的市場滲透。高昂的營運成本使得預算有限的實驗室無力購買必要的自動化液體處理系統，導致先進的結晶技術僅限於資金雄厚的機構使用。美國藥品研究與製造商協會 (PhRMA) 的一份報告凸顯了這一成本障礙的巨大影響，該報告指出，到 2024 年，其成員公司每年將在研發方面投入約 1000 億美元。如此龐大的資金需求，部分源自於技術效率低下，限制了結晶解決方案的潛在基本客群，並阻礙了其在大型製藥企業以外的廣泛應用。

市場趨勢

串行飛秒晶體學（SFX）的興起正在革新結構生物學，使人們能夠在室溫下觀察大分子動力學，這是傳統低溫冷卻技術無法實現的。該技術利用X光自由電子雷射發射超高亮度脈衝，在輻射損傷發生之前捕獲衍射數據，使研究人員能夠記錄生物過程的分子級動力學。這項技術對於即時理解快速酶反應和配體結合至關重要，並推動了市場對兼容高強度光源的專用樣品輸送系統的需求。該領域的一項重大進展是，美國能源局SLAC國家加速器實驗室於2024年9月宣布LCLS-II升級工程已完成，使該設施每秒可產生高達一百萬個X光脈衝，比之前的極限提高了8000倍。

同時，隨著製藥公司尋求降低藥物研發早期階段的固定基礎設施成本，外包給受託研究機構（CRO）的趨勢日益明顯。藥物研發人員不再維護成本高成本的內部結晶設施，而是越來越依賴外部合作夥伴的工業級平台來管理複雜的篩檢研究和結構解析。這種策略轉變使生物製藥公司能夠將固定資本支出轉化為可變營運成本，同時獲得廣泛的技術專長，而無需承擔維護設施的額外費用。無錫艾普泰克2024會計年度（截至2024年3月）的年度報告印證了這一轉變，該報告顯示，其提供全面早期藥物篩檢服務的無錫生物事業部營收達到25.5億元人民幣。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球蛋白質結晶市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（設備（液體處理設備、晶體成像設備）、耗材（試劑、試劑盒/篩檢、微孔盤等）、軟體和服務）
    • 透過技術手段（X光晶體學、冷凍電鏡、核磁共振波譜學等）
    • 依最終用戶（製藥/生技公司、學術研究機構）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美蛋白質結晶市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲蛋白質結晶市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區蛋白質結晶市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲蛋白質結晶市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲蛋白質結晶市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球蛋白質結晶市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Rigaku Corporation
  • Mettler-Toledo International Inc.
  • Corning Incorporated
  • Greiner Bio-One International GmbH
  • HAMPTON RESEARCH CORP
  • Jena Bioscience GmbH
  • Bruker Corporation
  • Creative Proteomics
  • Molecular Dimensions Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23962

The Global Protein Crystallization Market is projected to expand from USD 2.21 Billion in 2025 to USD 3.69 Billion by 2031, reflecting a compound annual growth rate of 8.92%. This technical process involves organizing protein molecules into ordered, repeating lattices to facilitate structural determination, primarily through X-ray crystallography. Growth in this sector is largely fueled by the rising adoption of structure-based drug design within pharmaceutical research and the essential need for high-resolution models of complex biological targets. Consequently, there is sustained demand for the specific reagents and automated liquid handling systems required for high-throughput screening. Data from the RCSB Protein Data Bank highlights the prevalence of this technique, noting that 9,200 biological macromolecule structures were solved using X-ray diffraction methods in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.21 Billion
Market Size 2031USD 3.69 Billion
CAGR 2026-20318.92%
Fastest Growing SegmentConsumables
Largest MarketNorth America

Despite this positive trajectory, the market faces significant hurdles due to the high failure rates associated with crystallizing membrane proteins and unstable macromolecular complexes. The inherent unpredictability of crystal formation frequently results in prolonged project timelines and increased research costs. These financial and technical barriers hinder the widespread adoption of crystallization workflows in smaller laboratories that lack extensive resources, effectively limiting market expansion in those sectors.

Market Driver

Increased research and development spending within the pharmaceutical and biotechnology sectors serves as a fundamental catalyst for the protein crystallization market, facilitating the acquisition of sophisticated instrumentation and high-purity reagents. As drug developers concentrate on discovering novel therapeutic targets, financial allocations to structural biology departments have grown to support the intricate process of elucidating macromolecular structures. This trend is evident in the budgets of major industry leaders; for instance, Merck & Co. reported in February 2024 that its full-year research and development expenses for 2023 reached $30.5 billion. Such substantial investment ensures the continuous operation of crystallization facilities needed to analyze the growing influx of biological candidates, a volume reflected by the FDA's Center for Drug Evaluation and Research approval of 55 novel therapeutics in 2024.

In parallel, technological breakthroughs in automation and high-throughput screening are transforming crystallization efficiency by minimizing human error and optimizing experimental density. The incorporation of artificial intelligence into liquid handling systems enables the accurate prediction of crystallization conditions, a vital component of structure-based drug design. These innovations are essential for validating computational models, as physical crystals remain the definitive standard for confirming atomic interactions. Highlighting this synergy, Google announced in May 2024 that its AlphaFold 3 model predicts protein-ligand interactions with 50% greater accuracy than conventional methods, creating a need for robust physical workflows to verify these predictions. Thus, the combination of automated hardware and computational tools is reducing barriers for analyzing complex targets and broadening the market's scope.

Market Challenge

The Global Protein Crystallization Market is significantly impeded by the high attrition rates encountered when crystallizing membrane proteins and unstable macromolecular complexes, which introduce considerable inefficiency into structural determination efforts. Since these biological targets are inherently difficult to stabilize, researchers frequently experience repeated experimental failures that lead to extended project timelines and the excessive consumption of expensive reagents. This unpredictability diminishes the throughput of crystallization workflows, directly undermining the industry's broader push for speed and automation in drug design initiatives.

Moreover, the financial strain caused by these failures restricts market penetration into smaller research segments. High operational costs prevent laboratories with limited budgets from acquiring necessary automated liquid handling systems, effectively restricting advanced crystallization capabilities to well-funded institutions. The magnitude of this cost barrier is illustrated by the Pharmaceutical Research and Manufacturers of America (PhRMA), which reported in 2024 that member companies invested approximately $100 billion in annual research and development. These immense capital requirements, driven in part by technical inefficiencies, limit the potential customer base for crystallization solutions and stall broader adoption outside of major pharmaceutical companies.

Market Trends

The rise of Serial Femtosecond Crystallography (SFX) is revolutionizing structural biology by allowing the visualization of macromolecular dynamics at room temperature, a feat not possible with standard cryo-cooled techniques. By utilizing X-ray free-electron lasers to emit ultra-bright pulses, this method captures diffraction data before radiation damage occurs, effectively enabling researchers to record molecular movies of biological processes. This capability is vital for understanding rapid enzymatic reactions and ligand binding in real time, driving the market toward specialized sample delivery systems that support high-intensity light sources. A key development in this area was announced by the Department of Energy's SLAC National Accelerator Laboratory in September 2024, revealing that the completed LCLS-II upgrade now allows the facility to generate up to one million X-ray pulses per second, an 8,000-fold increase over prior limits.

Simultaneously, there is a distinct trend toward outsourcing to Contract Research Organizations as pharmaceutical companies aim to minimize fixed infrastructure costs linked to early-stage discovery. Instead of upholding costly internal crystallization facilities, drug developers are increasingly relying on the industrial-scale platforms of external partners to manage complex screening campaigns and structural elucidation. This strategic shift enables biopharmaceutical firms to transform fixed capital expenditures into variable operational costs while gaining access to extensive technical expertise without the overhead of equipment maintenance. Evidence of this shift is found in WuXi AppTec's March 2024 annual report, which noted that revenue for its WuXi Biology segment, offering comprehensive early discovery screening services, reached RMB 2.55 billion.

Key Market Players

  • Rigaku Corporation
  • Mettler-Toledo International Inc.
  • Corning Incorporated
  • Greiner Bio-One International GmbH
  • HAMPTON RESEARCH CORP
  • Jena Bioscience GmbH
  • Bruker Corporation
  • Creative Proteomics
  • Molecular Dimensions Limited

Report Scope

In this report, the Global Protein Crystallization Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Crystallization Market, By Product

  • Instruments (Liquid Handling Instruments, Crystal Imaging Instruments)
  • Consumables (Reagents & Kits/Screens, Micro Plates, Others)
  • Software & Services

Protein Crystallization Market, By Technology

  • X-ray Crystallography
  • Cryo-electron Microscopy
  • NMR Spectroscopy
  • Others

Protein Crystallization Market, By End User

  • Pharmaceutical And Biotechnology Companies
  • Academic Research Institutes

Protein Crystallization Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Protein Crystallization Market.

Available Customizations:

Global Protein Crystallization Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Crystallization Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments( Liquid Handling Instruments, Crystal Imaging Instruments), Consumables( Reagents & Kits/Screens, Micro Plates, Others), Software & Services)
    • 5.2.2. By Technology (X-ray Crystallography, Cryo-electron Microscopy, NMR Spectroscopy, Others)
    • 5.2.3. By End User (Pharmaceutical And Biotechnology Companies, Academic Research Institutes)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Protein Crystallization Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Protein Crystallization Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Protein Crystallization Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Protein Crystallization Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End User

7. Europe Protein Crystallization Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Protein Crystallization Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End User
    • 7.3.2. France Protein Crystallization Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Protein Crystallization Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Protein Crystallization Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Protein Crystallization Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By End User

8. Asia Pacific Protein Crystallization Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Protein Crystallization Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End User
    • 8.3.2. India Protein Crystallization Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Protein Crystallization Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Protein Crystallization Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Protein Crystallization Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By End User

9. Middle East & Africa Protein Crystallization Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Protein Crystallization Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Protein Crystallization Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Protein Crystallization Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End User

10. South America Protein Crystallization Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Protein Crystallization Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Protein Crystallization Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Protein Crystallization Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Protein Crystallization Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Rigaku Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Mettler-Toledo International Inc.
  • 15.3. Corning Incorporated
  • 15.4. Greiner Bio-One International GmbH
  • 15.5. HAMPTON RESEARCH CORP
  • 15.6. Jena Bioscience GmbH
  • 15.7. Bruker Corporation
  • 15.8. Creative Proteomics
  • 15.9. Molecular Dimensions Limited

16. Strategic Recommendations

17. About Us & Disclaimer